Rigerna

Executive Summary

Rigerna Therapeutics is a preclinical-stage Chinese biotech founded in 2022, focused on developing innovative small interfering RNA (siRNA) therapeutics for genetic, rare, and chronic diseases. The company has built proprietary technology platforms—RIHOST®, RICMO®, and LICOD®—which enable rational nucleic acid design, chemical modification, and targeted in vivo delivery. Notably, its LICOD® platform is designed to overcome delivery barriers beyond the liver, potentially unlocking siRNA applications for extrahepatic tissues. Rigerna has raised $28 million to date and is advancing liver-targeting programs toward clinical entry, positioning itself in the rapidly growing siRNA field with a differentiated delivery approach.

Upcoming Catalysts (preview)

• Q2 2027IND filing for lead liver-targeting siRNA candidate70% success
• Q4 2026Series A/B financing round to support pipeline expansion75% success
• H1 2028Proof-of-concept data for extrahepatic delivery platform (LICOD®)40% success